Since 2017, the SGLT2 inhibitor, empagliflozin (Jardiance), and the Glucagon-like Peptide-1 (GLP-1) agonist, liraglutide (Victoza), have been recommended as the second line treatment to patients with T2DM and established CVD who do not receive adequate regulation of their diabetes with metformin [8]. The gene discussed is GCG; the disease is type 2 diabetes mellitus.